TLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Telix Pharmaceuticals Ltd (TLX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's recent resubmission of its NDA for TLX101-Px, coupled with positive analyst ratings and strong technical indicators, suggests significant growth potential. While the RSI indicates the stock is overbought, the positive pre-market momentum and strong catalysts make it a compelling long-term opportunity.
The MACD is positively expanding with a histogram value of 0.151, indicating bullish momentum. The RSI of 82.034 suggests the stock is overbought, but the pre-market price increase of 3.15% and converging moving averages support a positive trend. Key resistance levels are at R1: 8.489 and R2: 8.831, with the current pre-market price at 8.84 breaking above R2, signaling strong upward momentum.
Resubmission of the NDA for TLX101-Px to the FDA, which could lead to regulatory approval and market expansion.
Orphan Drug and Fast Track designations for TLX101-Px, enhancing its market potential.
Positive analyst ratings with increased price targets and a compelling risk/reward profile.
Concerns around regulatory approvals and a history of pre-tax losses in
Overbought RSI, which may lead to short-term profit-taking.
No financial data available for analysis.
Analysts are bullish on TLX. Citi raised the price target to $22.50 and maintained a Buy rating, citing the potential FDA approval of TLX101-Px. RBC Capital upgraded the stock to Outperform due to its compelling valuation and improved risk/reward profile.
